CASE REPORT

Treatment of unprotected left main coronary artery stenosis with a drug eluting stent in a heart transplant patient with allograft vasculopathy

G Matos, L Steen, F Leya


High risk angioplasty with drug eluting stent placement into an unprotected left main coronary artery in a heart transplant recipient with allograft vasculopathy is reported. Ten month angiographic follow up is reported. The literature is reviewed and current methods of revascularisation are described in detail. This is the first report of drug eluting stent use in this clinical situation.

Allograft vasculopathy is the main cause of death in heart transplant recipients surviving the first year of transplantation. Medical treatment has very limited efficacy in preventing allograft vasculopathy. Coronary artery bypass grafting (CABG) is seldom possible because of the diffuse nature of the disease and is often a high risk procedure, carrying a 40–80% perioperative mortality. Retransplantation has worse prognosis than the first transplant procedure and is limited by a severe shortage of donor organs. Therefore, percutaneous coronary intervention (PCI) has been attempted and good immediate success and a varying rate of restenosis have been reported.

Unprotected left main coronary artery balloon angioplasty is technically feasible but procedural and three year mortality rates are high: 9% and 64% for elective cases, and 50% and 70% for acute myocardial infarction. Stenting improved procedural success rates (> 95%) in highly selected patients and improved restenosis in 14–23%. For elective stenting in patients with left ventricular ejection fraction > 40%, 86% event-free survival was reported at six months.

We report the first case of the treatment of unprotected left main coronary artery stenosis in a heart transplant recipient with drug eluting stent placement.

CASE REPORT

Significant allograft vasculopathy of the left main coronary artery was diagnosed in a 58 year old man. Subjective symptoms were worsening fatigue and decreasing exercise capacity. A dobutamine echocardiogram showed normal baseline systolic function and no wall motion abnormalities with stress. Coronary angiogram showed significant focal coronary artery disease in the proximal segments of the left anterior descending, circumflex, and right coronary arteries, as well as a shelf-like plaque in the proximal to mid-left main stem (fig 1A, B). The focal nature of obstructive lesions in the proximal coronary tree made angioplasty a technically feasible alternative. The patient had had three previous sternotomies for open heart surgery. Because of the high risk of CABG in this clinical presentation, the patient requested a staged series of angioplasties instead of another operation.

The patient’s medical history was significant for orthotopic heart transplantation in 1989 for valvar cardiomyopathy, hypertension, and hypercholesterolaemia. The patient had had a single episode of documented grade 1A, focal, mild, acute cellular rejection in 2001. Home medications were aspirin, clopidogrel, atenolol, pravastatin, amiodarone, prednisone, and cyclosporine. Complete blood count and a metabolic panel, including normal serial creatinine concentrations, were within normal limits. Low density lipoprotein ranged between 2.2–2.9 mmol/l, high density lipoprotein between 0.7–0.96 mmol/l, and triglyceride concentrations between 0.71–1.9 mmol/l over the preceding two years. He had previously undergone the following interventions: 2.5 × 23 mm Cypher stent placement into the proximal right coronary artery and 2.5 × 18 mm Cypher stent placement into the proximal circumflex coronary artery followed after...
several months with a 3 × 28 mm Cypher stent placement into the proximal left anterior descending coronary artery.

The final, third phase of the above series of angioplasties was the intervention on the mid left main coronary artery stenosis (fig 2A, B). It was performed last so that this high risk procedure could be performed with an open vascular bed in the more distal segments. Also, the 3.5 × 8 mm Cypher stent was not available in our institution at the time of the first two phases of the intervention. Intra-aortic balloon pump and temporary pacemaker were placed electively, and cardiovascular surgical back up was ascertained. Intravenous eptifibatide was started in the catheterisation laboratory and continued for 12 hours after the procedure. The left main coronary artery was intubated with a 6 French Judkins left guide catheter with side holes and the lesion was crossed with a 0.014 inch Sport coronary guidewire. The lesion was dilated with 2.5 × 20 mm Raptor balloon at 6 atm. It was positioned to cover the left main stem only, with the remainder of the balloon situated in the aorta to avoid the “watermelon seeding” phenomenon seen with shorter balloons. A 3.5 × 8 mm Cypher stent was deployed in the left main stem at 14 atm with good results (fig 3A, B).

Intravascular ultrasound showed appropriate sizing and good apposition of the stent to the vessel wall. There was no residual stenosis or evidence of complications. The intra-aortic balloon and the pacemaker were removed, and both femoral arteries were closed with closing device. The patient left the hospital the following day. On the basis of randomised studies, one year treatment with clopidogrel was recommended. On clinical follow up at six weeks after the angioplasty, the patient commented on improvements in his ability to perform sustained exercise. Five and 10 months after the procedure, the patient had elective follow up angiograms. They showed patent stents in the left main, right, and circumflex coronary arteries. There was minimal angiographic restenosis in the left anterior descending artery stent.

DISCUSSION

Allograft vasculopathy is the leading cause of death and morbidity after the first year of transplantation. Its prevalence is high: 11%, 22%, and 45% at one, two, and four years after transplantation, respectively. The accelerated coronary artery disease involves both the epicardial and the intramyocardial arteries. Its diagnosis is difficult because of the absence of angina in the denervated heart and the low sensitivity of non-invasive stress testing. The first manifestation of allograft vasculopathy is often congestive heart failure, ventricular arrhythmias, or sudden death. The ineffective medical treatment and the limited suitability of CABG and retransplantation have motivated interest in PCI for the subset of heart transplant recipients presenting with allograft vasculopathy in proximal segments. Schnetzler and colleagues reported 94.3% primary success (50% residual stenosis) in 53 lesions. Two of these patients had symptomatic left main stenosis, which were dilated with success. One patient, however, had restenosis and later underwent CABG with success. There was no periprocedural mortality and the six month restenosis rate (defined as percentage stenosis > 50%) was 32.5%. Musci and colleagues described 46 of 124 patients who underwent 76 PCIs for allograft vasculopathy. The primary success rate was 96% and the angiographic restenosis was 42% at 11 months. There was no...
The effect of drug eluting stents on left main restenosis in heart transplant recipients needs further investigation, as this treatment modality may be an effective alternative for this very high risk group of patients.

Authors’ affiliations
G F Matos, L Steen, F Leya, Department of Cardiology, Loyola University Medical Center, Maywood, Illinois, USA

References
Treatment of unprotected left main coronary artery stenosis with a drug eluting stent in a heart transplant patient with allograft vasculopathy

G Matos, L Steen and F Leya

Heart 2005 91: e11
doi: 10.1136/hrt.2004.045096

Updated information and services can be found at:
http://heart.bmj.com/content/91/2/e11

These include:

References
This article cites 21 articles, 1 of which you can access for free at:
http://heart.bmj.com/content/91/2/e11#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/